Home > Protocol Summaries: Compounds > emicerfont Protocol Summaries: emicerfont GSKStudy ID Phase Title Status CRH108571 Phase 1 Double-blind, randomized, placebo and Alprazolam-controlled three-period crossover incomplete block design study to compare putative anxiolytic-like fRMI activity of GW876008 and GSK561679 after single-dose administration in subjects with Social Anxiety Disorder (SAD) Completed CRI103147 phase 1 A Phase IIa experimental medicine study assessing alterations in Regional Cerebral Blood Flow by functional magnetic resonance imaging (fMRI) in female IBS patients and healthy controls following single doses of GW876008, a corticotrophin releasing factor 1 receptor antagonist (CRF1-RA) Completed CRI105626 phase 2 A randomised, double-blind, placebo-controlled, crossover study to evaluate efficacy and safety of the CRF1 receptor antagonist GW876008 in patients with Irritable Bowel Syndrome Completed
